^
Association details:
| Biomarker: | Chr del(3)(q14.2) |
|---|---|
| Cancer: | Leiomyosarcoma |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
4280 / 4 - Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma
Published date:
05/15/2020
Excerpt:
From 82 archival primary tumor or metastatic LMS samples collected prior to study entry, 78 specimens were available for low-coverage whole genome sequencing...In the ERI-treated group, gains of 4q26, 20p12.2, 13q13.3, 8q22.2, 8q13.2 and loss of 1q44 had a negative impact on progression-free survival (PFS) (p<0.05; log rank test), while loss of 2p12 was a positive prognosticator . Gains of 4q22.1 and losses of 3q14.2, 2q14.1 and 11q25 had a negative impact on OS in ERI-treated patients.
